Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph early_phase_1
2
67%
Ph phase_1
1
33%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 1Safety & dosage
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (66.7%)
Phase 11 (33.3%)

Trials by Status

not_yet_recruiting267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia

NCT07416032
not_yet_recruitingearly_phase_1

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

NCT07392528
recruitingphase_1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

NCT07315087

Clinical Trials (3)

Showing 3 of 3 trials
NCT07416032Early Phase 1

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia

Not Yet Recruiting
NCT07392528Early Phase 1

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Not Yet Recruiting
NCT07315087Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3